The FDA has approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia, according to a press release from Paratek Pharmaceuticals.Omadacycline (Nuzyra, Paratek Pharmaceuticals) is a novel antibiotic with once-daily oral and IV formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure